Fig. 5: PBZ has anti-leukemia effects on AML-PDX cells in vitro and in vivo. | Communications Biology

Fig. 5: PBZ has anti-leukemia effects on AML-PDX cells in vitro and in vivo.

From: Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes

Fig. 5

AML-PDX cells were treated with DMSO, ABZ (100 nM), or PBZ (100 nM) for 48 h, and the expressions of monocyte markers (a), morphology (b), apoptosis (c), and KLF4/DPYSL2A mRNA expression (d) were examined in vitro. (e). Schematic illustration of an in vivo study. NOG mice were injected with AML-PDX cells. One week later, they were administered a control vehicle, ABZ, or PBZ (100 mg/kg body weight, orally, once daily). Five weeks after AML-PDX cell transplantation, the mice were assessed for chimerism and cell differentiation. (f) Chimerism percentages were compared. (g) Expression of monocyte markers (CD11b and CD14) was compared using FCM on AML-PDX cells sorted from mouse bone marrow. h Morphological changes in AML-PDX cells from mouse bone marrow were examined. i Survival rates of mice treated with DMSO, ABZ, or PBZ were compared. Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001. ns, not significant.

Back to article page